Insilico Approach for Identification of Novel Inhibitors Against SRNA9 Protein
Posted: 18 Feb 2020
Date Written: February 16, 2020
Lymphoma is a distinctive blood cell cancer effecting lymphocytes, immune cells which are crucial in human health and acts against many diseases. SRNA9 belongs to a serpin family involves in B cell maturation and naive B cell maintainance. SRNA9 interpretation is precise to germinal centre B-cells and germinal centre B-cell-derived lymphomas. SRNA9 in combination with bcl-6 and GCET2 develop a germinal centre B-cell signature which is find in diffuse large B-cell lymphoma (DLBCL) and high level expression of GCET1 is observed in many lymphomas like Follicular lymphoma (FL), DLBCL, nodular lymphocyte predominant Hodgkin lymphoma,T-cell/histiocyte rich B-cell lymphoma and Burkitt lymphoma (1,2,3). A 3D structure of SRNA9 was evaluated by using homology modeling techniques and protein energy minimized by NAMD server. The resulting 3D structure of SRNA9 was validated and active site identification is carried out by using site map and literature studies. Structure-based virtual screening study with the structural asinex database was carried out to identify a new ligand molecules showing more affinity towards SRNA9. The molecules with more appropriate docking scores and acceptable ADME and prime MMGBSA are treated as dominant SRNA9 inhibitors for cancer treatment.
Keywords: Lymphoma, FL,DLBCL,NAMD server, Virtual Screening
Suggested Citation: Suggested Citation